Redeye updates on Raketech ahead of Q3-results (due 14 November) where we expect a soft quarter with...
We expect Suominen to deliver another quarter of improving profitability, driven by increased volume...
Q3e: Germany continues to weigh, US expected to be stable Lowered estimates in Germany on prolonged ...
Adj. EBITA of EUR 8.2m (ABGSCe EUR 5.0m), Finland outperforms '24e up on Q3 beat, Norway estimates l...
EBIT SEK 40m vs. ABG SEK 47m; Q4e likely weaker Pulp moving into more challenging territory – prices...
Redeye resumes coverage of Nanologica following the announced outcome of its rights issue, which sec...
Enrad AB:s nettoomsättning på ca 8,0 MSEK under kv3 2024 överensstämde med vår prognos före rapporte...
Raute’s EUR 46.4m Q3 revenue was soft relative to our estimate, yet the EUR 6.
Exel’s Q3 revenue continued to grow y/y, albeit not quite as fast as was estimated since the figures...
Marimekko reports its Q3 results on 6th of November.
Q3 2024 profit before loan losses came in at DKK 66m, DKK 7m (10%) below our estimate.
Konjunkturen är svag och volymerna minskar men kontraktstillverkaren AGES Industri tar nya marknadsa...
Sales +1% vs cons, adj. EBITA +1% vs cons Cons. EBITA estimate revisions slightly positive Improved ...
Redeye returns with a more in-depth take on Devyser’s Q3 report.
Q3 Sales and Profits beat estimates, but the economic downturn affects demand.
Sprint Bioscience delivered Q3 sales within the recent range at SEK 14.
Redeye comments on Iconovo’s announcement regarding Amneal’s completed clinical pharmacokinetic pilo...
Redeye has received several questions regarding Acconeer's milestone payments from Alps Alpine.
Redeye is making some downward revisions to our near-term forecasts on the back of softer Q3 numbers...
